<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="table1-1759720X20947296" orientation="portrait" position="float">
 <label>Table 1.</label>
 <caption>
  <p>Potential antiviral efficacy of DMARDs and immunosuppressants for SARS-CoV-2.</p>
 </caption>
 <alternatives>
  <graphic xlink:href="10.1177_1759720X20947296-table1" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <table frame="hsides" rules="groups">
   <colgroup span="1">
    <col align="left" span="1"/>
    <col align="char" char="." span="1"/>
    <col align="char" char="." span="1"/>
    <col align="char" char="." span="1"/>
   </colgroup>
   <thead>
    <tr>
     <th align="left" rowspan="1" colspan="1">Medications</th>
     <th align="left" rowspan="1" colspan="1">Proposed antiviral mechanisms</th>
     <th align="left" rowspan="1" colspan="1">
      <italic>In vitro</italic>
     </th>
     <th align="left" rowspan="1" colspan="1">Clinical report</th>
    </tr>
   </thead>
   <tbody>
    <tr>
     <td rowspan="1" colspan="1">
      <bold>Chloroquine</bold>
      <break/>
      <bold>HCQ</bold>
     </td>
     <td rowspan="1" colspan="1">(1) Increase endosomal pH required for virus/cell fusion
      <break/>(2) Interfere with the glycosylation of cellular receptors
     </td>
     <td rowspan="1" colspan="1">✓</td>
     <td rowspan="1" colspan="1">✓ Cohort (
      <italic>n</italic> = 42): negative RT-PCR rate on day 6
      <break/> HCQ group: 70% (13/20)
      <break/> Control group: 12.5% (2/16)
      <break/> HCQ + azithromycin group: 100% (6/6)
      <sup>
       <xref rid="bibr7-1759720X20947296" ref-type="bibr">7</xref>
      </sup>
      <break/>✗ RCT (
      <italic>n</italic> = 30): no significant difference
      <sup>
       <xref rid="bibr8-1759720X20947296" ref-type="bibr">8</xref>
      </sup>
      <break/>✓ Open label, no control group (
      <italic>n</italic> = 80): with azithromycin, 65/80 improved clinical outcomes
      <sup>
       <xref rid="bibr9-1759720X20947296" ref-type="bibr">9</xref>
      </sup>
      <break/>✓ RCT (
      <italic>n</italic> = 62): significant improvement in time to clinical recovery and radiologic change (
      <italic>p</italic> &lt; 0.05)
      <sup>
       <xref rid="bibr10-1759720X20947296" ref-type="bibr">10</xref>
      </sup>
      <break/>✓ RCT (
      <italic>n</italic> = 22): shorten hospital days and greater radiologic improvement, but not significant compared to control (Lopinavir/Ritonavir)
      <sup>
       <xref rid="bibr11-1759720X20947296" ref-type="bibr">11</xref>
      </sup>
      <break/>✗ RCT (
      <italic>n</italic> = 150): only significant in CRP reduction (
      <italic>p</italic> = 0.045)
      <sup>
       <xref rid="bibr12-1759720X20947296" ref-type="bibr">12</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">
      <bold>Baricitinib</bold>
     </td>
     <td rowspan="1" colspan="1">(1) Regulate endocytosis of virus by inhibiting AAK1, GAK.
      <break/>(2) Reduce cytokines including IL-2, IL-6, IL-10, G-CSF, and IFN-γ
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ 
      <italic>n</italic> = 4, improved clinically and in laboratory data.
      <sup>
       <xref rid="bibr13-1759720X20947296" ref-type="bibr">13</xref>
      </sup>
      <break/>✓ Placebo-controlled, open-label study (
      <italic>n</italic> = 24): significant improvement in baricitinib group
      <sup>
       <xref rid="bibr14-1759720X20947296" ref-type="bibr">14</xref>
      </sup>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">
      <bold>Cyclosporine A</bold>
     </td>
     <td rowspan="1" colspan="1">(1) Target cyclophilin D to inhibit MPTP opening and rescues mitochondria from apoptosis.
      <break/>(2) MDA5, a putative cytoplasmic receptor of SARS-CoV-2, could be reversed by calcineurin inhibitors
     </td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">
      <bold>MMF</bold>
      <break/>MPA
     </td>
     <td rowspan="1" colspan="1">Inhibit DHODH and IMPDH</td>
     <td rowspan="1" colspan="1">✓</td>
     <td rowspan="1" colspan="1"/>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">
      <bold>Thalidomide</bold>
     </td>
     <td rowspan="1" colspan="1">Suppress pro-inflammatory cytokines (TNF-α, IL-8) through inhibition of NF-κB</td>
     <td rowspan="1" colspan="1"/>
     <td rowspan="1" colspan="1">✓ 
      <italic>n</italic> = 1: 45 years, woman
      <sup>
       <xref rid="bibr15-1759720X20947296" ref-type="bibr">15</xref>
      </sup>
     </td>
    </tr>
   </tbody>
  </table>
 </alternatives>
 <table-wrap-foot>
  <fn id="table-fn1-1759720X20947296">
   <p>AAK1, AP2-associated protein kinase 1; CRP, C-reactive protein; DHODH, dihydroorotate dehydrogenase; GAK, cyclin G-associated kinase; G-CSF, granulocyte-colony-stimulating factor; IL, interleukin; HCQ, hydroxychloroquine; IFN, interferon; IMPDH, inosine monophosphate dehydrogenase; MDA5, melanoma-differentiation-activated protein 5; MMF/MPA, mycophenolate mofetil/mycophenolic acid; MPTP, mitochondrial permeability transition pore opening; RCT, randomized-controlled trial; RT-PCR, real-time polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TNF, tumor necrosis factor.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
